^
    Back
    Association details:
    Biomarker:RET fusion
    Cancer:Lung Adenocarcinoma
    Drug:Gavreto (pralsetinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    GAVRETO is a kinase inhibitor indicated for treatment of:...Adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Cancer Res
    Title:

    Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma

    Published date:
    06/03/2021
    Excerpt:
    Eighty-four organoids were established from patients with advanced lung adenocarcinoma….We demonstrated efficacy of poziotinib against ERBB2 exon 20 insertions and pralsetinib against RET-fusions...
    DOI:
    10.1158/1078-0432.CCR-20-5026